We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Sr4.2
Strontium Research
Mostly mechanism / observational
8 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Strontium studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2002–2025 with a typical study size of 191 participants.
Based on 8 studies · 3 meta-analyses · 2 RCTs · 191 total participants
Confidence
High confidence
By outcome
Bone healthFracture-risk reduction shown for prescription ranelate; OTC citrate is far less proven · 12+ months
Mostly mechanism / observational8 studies
Safety profile
Too few graded studies1 study
Steady research
2 studies in the last 5 years · Latest meta-analysis: 2024
200220132025
1Review2025
In plain English: We consider here targeted therapeutics that are already in clinical practice, as well as the most promising novel agents that are now under development: antibodies, siRNAs, aptamers, and small molecules.
Omelchenko V, Koval V, Slazhneva N, Bondarenko N, Shatunova E, Vorobyeva M, Korolev M. · International journal of molecular sciences (2025)
Targeting pathways underlying bone metabolism could significantly improve the therapeutic options and provide new tools in the fight against osteoporosis.
Among them, there are bisphosphonates, strontium ranelate, calcitonin, estrogen-progestin therapy, selective estrogen receptor modulators, and parathyroid hormone analogues.
Otherwise, they suffer from certain disadvantages, such as adverse effects, including serious ones, and limitations associated with comorbidity.
In plain English: Conclusion Collectively, our study suggests that AFMs improve bone quality, which explains their anti-fracture ability that is not fully accounted for by increased BMD in osteoporosis patients.
Sharma S, Shankar V, Rajender S, Mithal A, Rao SD, Chattopadhyay N. · Frontiers in endocrinology (2024)
Pooled analysis showed that AFMs significantly decreased cortical bone crystallinity [standardized difference in means (SDM) -1.394] and collagen maturity [SDM -0.855], and collagen maturity in cancellous bone [SDM -0.631].
Additionally, anti-resorptives (bisphosphonates and denosumab) significantly increased crystallinity [SDM 0.387], mineral-matrix ratio [SDM 0.771], microhardness [SDM 0.858], and contact hardness [SDM 0.952] of cortical bone.
Restricted analysis of only bisphosphonate-treated studies showed a significant decrease in collagen maturity [SDM -0.650] in cancellous bone and an increase in true hardness [SDM 1.277] in cortical bone.
In plain English: A pooled analysis of large RCTs (SOTI/TROPOS) found strontium ranelate reduced vertebral fracture risk in postmenopausal osteoporosis, independent of baseline bone-turnover markers.
Collette J et al. · Osteoporos Int (2010)
Strontium RANELATE reduced vertebral fracture risk in postmenopausal osteoporosis
Pooled from large randomized trials (SOTI/TROPOS)
This is the prescription DRUG ranelate — NOT the OTC strontium citrate supplement
In plain English: A pooled analysis linked early bone-turnover-marker changes to bone-density (BMD) response — but markers were NOT significantly associated with fracture incidence.
Bruyere O et al. · Osteoporos Int (2010)
Early bone-marker changes tracked the BMD response
Markers were NOT significantly associated with fracture incidence
Pharmacodynamic analysis of ranelate (not citrate)